



SUBSCRIBE

IPO Report

22nd July 26

Snapshot

Company provide end-to-end solutions for the manufacture of precision engineering components using metal injection molding (“MIM”) technology. Company’s capabilities include mold designing and tooling, coupled with finishing and assembly operations. With over 25 years of experience in the MIM industry, company is the largest manufacturer globally of precision engineering components using MIM technology, with a market share of 6.8% in terms of revenue from MIM in Calendar Year 2025 and have held this position for the last six years. Company’s product portfolio caters to automotive, defence, medical, consumer, and aerospace sectors, and company manufactured over 9,000 types of products in Fiscal 2026.

VALUATION

Company is bringing the issue at price band of Rs 461-485 per share at p/e multiple of 45x on post issue FY26 PAT basis.

Company has global leadership in manufacturing precision engineering components using MIM technology. Company has long-standing relationships with Indian and global OEM customers along with diversified product portfolio catering to applications across multiple industries. Company has backward integrated, dual-shore manufacturing capabilities with focus on efficiency .Hence, we recommend “Subscribe” to issue.

Price Band (Rs./Share)	461-485
Opening date of the issue	23rd July '2026
Closing Date of the issue	13th July '2026
No of shares pre issue	48,41,53,072 Eq Shares
Issue Size	Rs 3648-3812 Cr
OFS	68,291,022 Eq Shares
Fresh issue	Rs 500 Cr
Employee Discount	Rs 45/share
Face Value (Rs/ share)	Rs 1/share
Bid Lot	30

BIDDING DETAILS

QIBs (Including Anchor)	50% of the offer- 3,92,09,428 Eq Shares
Non-Institutional	15% of the offer - 1,17,62,829 Eq Shares
Retail	35% of the offer -2,74,46,600 Eq Shares
Employee Reservation	2,00,000 Eq Shares
Lead managers	Axis Capital, HDFC Bank, ICICI Securities, Kotak Mahindra Capital, SBI Capital Markets
Registrar to the issue	MUFG Intime India Pvt Ltd

WHAT WE LIKE

Global leadership in manufacturing precision engineering components using MIM technology

Company is the largest manufacturer globally of precision engineering components using MIM technology with a market share of 6.8% in terms of revenue from MIM in Calendar Year 2025 and have held this position for the last six years. With company’s experience and capabilities in mold designing, tooling, product development as per design specifications and material selection, company offer end-to-end solutions to the manufacturing needs of its customers.

Diversified product portfolio catering to applications across multiple industries

Company have a diverse product portfolio that serves customers across various industries, including automotive OEMs, and manufacturers of defence products, medical devices, consumer durables, and aerospace components. For the automotive industry, company manufacture components used in vehicle safety, fuel systems, powertrains, and interior applications, all of which are essential for automobiles. Company’s products in the defence industry include parts for firearms, such as triggers, hammers and sights. In the medical industry, company produce components for surgical devices used in endoscopy, laparoscopy, dental robotics and orthopedics.

Backward integrated, dual-shore manufacturing capabilities with focus on efficiency

Company operate 15 manufacturing facilities, of which, six are located in India, six in the United States, two in the United Kingdom and one in Mexico. The strategic location of company’s manufacturing facilities in India provides company with cost and logistical advantages. Company’s dual-shore manufacturing, with manufacturing capabilities both in India and countries such as the United States, United Kingdom and Mexico, enables company to serve both Indian and global OEMs, helping Company benefit from economies of scale.



COMPANY BACKGROUND

Over the years, company have implemented a range of manufacturing technologies to enhance its product offerings to customers. In addition to MIM technology, company leverage technologies such as investment casting, precision machining, ceramic injection molding and metal three-dimensional (“3D”) printing. These technologies have strengthened company’s manufacturing capabilities and enabled company to address the evolving needs of customers across industries. Company’s product portfolio caters to automotive, defence, medical, consumer, and aerospace sectors, and company manufactured over 9,000 types of products in Fiscal 2026.

Product Profile

Automotive Products Group (“APG”): Company’s product range includes components used in vehicle safety, fuel systems, powertrains, and interior applications, all of which are essential for automobiles.

Defence Products Group (“DPG”): Company manufacture firearm components with applications in the defence industry such as triggers, hammers and sights.

Medical Products Group (“MPG”): Company manufacture a range of components for surgical devices in fields such as endoscopy, laparoscopy, dental robotics and orthopedics.

Consumer Products Group (“CPG”): Company supply products for fashion accessories, crossbow parts, cellphone components, tools and hardware applications.

Aerospace Products Group (“Aerospace”): Company manufacture components such as manifolds and precision housings, adaptors and tees, servo motor housing, nozzles and locking rings and clevises and brackets for original equipment manufacturers (“OEMs”) in the aerospace industry.

Company operate 15 manufacturing facilities, of which, six are located in India, six in the United States, two in the United Kingdom (“UK”) and one in Mexico. Over the years, company have expanded company’s manufacturing capabilities and as of March 31, 2026, company have the world’s largest installed capacity for MIM products.

Company’s dual-shore manufacturing, with manufacturing capabilities both in India and countries such as the United States, the UK and Mexico coupled with company’s scale of operations, technical know-how and mold design capabilities, helps company compete with other global precision engineered product manufacturers. Company’s manufacturing model enables it to serve both Indian and global OEMs, helping company benefit from economies of scale. Company’s manufacturing capabilities enable it to cater to the needs of customers

who require domestic manufacturing for their components. Additionally, having a local base offers additional supply chain security for customers who do not necessarily require domestic sourcing, in case of unforeseen events. Company’s diverse capabilities allow it to service the customers globally, which has established company as an export-oriented company with customers across North America, Europe and South East Asia.

OBJECTS OF OFFER

The Offer comprises the Fresh Issue and the Offer for Sale.

Requirement of funds

Company propose to utilise the Net Proceeds towards funding the following objects:

1. Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by company; and
2. General corporate purposes.

RISKS

Company derive a significant portion of its revenue from its top 10 customers, who contributed 38.41%, 38.94% and 42.00% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. The loss of such customers or a significant reduction in demand of company’s products from these customers could have an adverse effect on its business, results of operations, financial condition and cash flows.

Source:RHP



Consolidated Financials

(Rs in Mn)

Financials	FY24	FY25	FY26
Total Revenue (A)	28703.95	33295.77	41929.85
Total Expenditure (B)	21269.33	23969.8	31220.62
EBIDTA	7434.62	9325.97	10709.23
EBIDTA Margin	25.90	28.01	25.54
Other Income	299.87	443.95	1277.17
Depreciation	1743.64	1988.09	2200.64
EBIT	5990.85	7781.83	9785.76
Interest	874.06	961.02	1668.00
PBT	5116.79	6820.81	8117.76
Share of profit in Asso	0.00	0.00	0.00
PBIT	5116.79	6820.81	8117.76
Exceptional	764.74	1010.78	780.36
PBT	4352.05	5810.03	7337.40
Tax	1514.71	1572.69	2001.97
PAT	2837.34	4237.34	5335.43
NPM	9.88	12.73	12.72
ROE%	14.01	19.94	21.26
EPS	5.89	8.79	11.06
Eq Cap	482.03	482.03	484.15
Net Worth	20,505.11	21,994.34	28,195.54

(Source: RHP)



DISCLAIMER

HEM Securities Limited ("Research Entity or HSL") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services, merchant banking services, Portfolio Management Services and other related activities. Broking services offered by HEM Securities Limited are under SEBI Registration No.: INZ000168034.

This Report has been prepared by HEM Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH100002250 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. This should not be construed as invitation or solicitation to do business with HSL. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject HSL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. HSL reserves the right to make modifications and alterations to this statement as may be required from time to time. HSL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. HSL is committed to providing independent and transparent recommendation to its clients. Neither HSL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

HSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.